首页 中华消化杂志 2020年40卷12期 2020年中国肠易激综合征专家共识意见
中华消化杂志
期刊首页
过刊列表
高级检索
稿件发表
• 共识与指南 •
ENGLISH ABSTRACT
2020年中国肠易激综合征专家共识意见
中华医学会消化病学分会胃肠功能性疾病协作组 
中华医学会消化病学分会胃肠动力学组
作者及单位信息
·
DOI： 10.3760/cma.j.cn311367-20201116-00660
Chinese expert consensus of irritable bowel syndrome in 2020
Study Group of Functional Gastrointestinal Disorders，Study Group of Gastrointestinal Motility
Chinese Society of Gastroenterology，Chinese Medical Association
Authors Info & Affiliations
Study Group of Functional Gastrointestinal Disorders，Study Group of Gastrointestinal Motility
Chinese Society of Gastroenterology，Chinese Medical Association
·
DOI： 10.3760/cma.j.cn311367-20201116-00660
18739
4557
0
8
206
40
扫描转手机阅读
下载中华医学期刊APP阅读更流畅 体验更丰富
PDF下载
APP内阅读
摘要
IBS是临床常见病，近年来对其认识不断更新，为更好地指导我国IBS的基础研究和临床诊治，中华医学会消化病学分会胃肠功能性疾病协作组牵头，组织国内相关领域多名专家对IBS的定义与病因流行病学、病因与发病机制、诊断和治疗进行讨论投票，最终形成本专家共识意见。
肠易激综合征;专家共识;诊断;治疗;流行病学
引用本文
中华医学会消化病学分会胃肠功能性疾病协作组,中华医学会消化病学分会胃肠动力学组. 2020年中国肠易激综合征专家共识意见[J]. 中华消化杂志,2020,40(12)：803-818.
DOI:10.3760/cma.j.cn311367-20201116-00660PERMISSIONS
Request permissions for this article from CCC.
评价本文
*以上评分为匿名评价
本文评分
0分
[累计0个]
向我们报错
版权归中华医学会所有。
未经授权，不得转载、摘编本刊文章，不得使用本刊的版式设计。
除非特别声明，本刊刊出的所有文章不代表中华医学会和本刊编委会的观点。
近些年，国内外研究者对IBS的临床实践和研究不断深入，提出了新的认识与概念。2016年罗马Ⅳ标准颁布后，我国学者进行了许多研究，也提出了符合我国国情的观点，因此，在2015年中国IBS专家共识意见的基础上，本专家组组织国内专家对IBS共识意见进行了更新。本专家共识意见的修订采用国际通用的Delphi程序，首先成立共识意见工作小组，在检索Medline、Embase、Cochrane图书馆和万方数据知识服务平台相关文献的基础上，起草共识意见条目，先后进行4轮线上讨论和1轮线下讨论，最后邀请全国相关领域专家进行线下讨论与投票，达成包括定义与流行病学、病因与发病机制、诊断和治疗共29条共识意见。
共识意见推荐级别分为6个等级：(A＋)非常同意；(A)同意但有少许保留意见；(A-)同意但有较多保留意见；(D-)不同意但有较多保留意见；(D)不同意但有少许保留意见；(D＋)完全不同意。投票程序规定，同意推荐(A＋、A、A-)比例≥80%的条目方可通过，<80%的条目将被删除。条目的证据分为4个等级：高质量，进一步研究也不可能改变该评估结果的可信度；中等质量，进一步研究很有可能影响该评估结果的可信度，且可能改变该评估结果；低质量，进一步研究极有可能影响该评估结果的可信度，且很可能改变该评估结果；极低质量，任何评估结果都很不确定。
试读结束，您可以通过登录机构账户或个人账户后获取全文阅读权限。
已是订阅账户?
登录
参考文献
[1]
Pimentel M , Talley NJ , Quigley EM ,et al. Report from the multinational irritable bowel syndrome initiative 2012[J]. Gastroenterology, 2013，144(7):e1-e5. DOI:
10.1053/j.gastro.2013.04.049
.
[2]
Xiong LS , Gong XR , Siah KT ,et al. Rome Foundation Asian Working Team report: real world treatment experience of Asian patients with functional bowel disorders[J]. J Gastroenterol Hepatol, 2017，32(8):1450-1456. DOI:
10.1111/jgh.13730
.
[3]
熊理守，时权，陈旻湖，等. 消化专科门诊肠易激综合征患者123例的临床特征与就医情况调查[J]. 中华消化杂志， 2015，35(7):476-477. DOI:
10.3760/cma.j.issn.0254-1432.2015.07.013
.
[4]
Bai T , Xia J , Jiang YD ,et al. Comparison of the Rome Ⅳ and Rome Ⅲ criteria for IBS diagnosis: a cross-sectional survey[J]. J Gastroenterol Hepatol, 2017，32(5):1018-1025. DOI:
10.1111/jgh.13642
.
[5]
中华医学会消化病学分会胃肠功能性疾病协作组，中华医学会消化病学分会胃肠动力学组. 中国肠易激综合征专家共识意见(2015年，上海)[J]. 中华消化杂志， 2016，36(5):299-312. DOI:
10.3760/cma.j.issn.0254-1432.2016.05.005
.
[6]
Degen LP , Phillips SF . How well does stool form reflect colonic transit？[J]. Gut， 1996，39(1):109-113. DOI:
10.1136/gut.39.1.109
.
[7]
Lewis SJ , Heaton KW . Stool form scale as a useful guide to intestinal transit time[J]. Scand J Gastroenterol， 1997，32(9):920-924. DOI:
10.3109/00365529709011203
.
[8]
Hungin AP , Whorwell PJ , Tack J ,et al. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40 000 subjects[J]. Aliment Pharmacol Ther, 2003，17(5):643-650. DOI:
10.1046/j.1365-2036.2003.01456.x
.
[9]
Xiong LS , Chen MH , Chen HX ,et al. A population-based epidemiologic study of irritable bowel syndrome in South China: stratified randomized study by cluster sampling[J]. Aliment Pharmacol Ther, 2004，19(11):1217-1224. DOI:
10.1111/j.1365-2036.2004.01939.x
.
[10]
Lovell RM , Ford AC . Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis[J]. Clin Gastroenterol Hepatol， 2012，10(7):712-721. DOI:
10.1016/j.cgh.2012.02.029
.
[11]
姚敏，陈燕萍，周惠清，等. 我国南方青少年肠易激综合征流行病学调查[J]．临床儿科杂志， 2007，25(10):835-839. DOI:
10.3969/j.issn.1000-3606.2007.10.011
.
[12]
周惠清，李定国，宋艳艳，等．中国西部地区城市青少年肠易激综合征现况调查[J]. 上海交通大学学报(医学版)， 2009，29(5):581-583，606. DOI:
10.3969/j.issn.1674-8115.2009.05.024
.
[13]
Sperber AD , Bangdiwala SI , Drossman DA ,et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study[J/OL]. Gastroenterology, 2020，12:S0016-5085(2020-04-12)[2020-11-16]. https://doi.org/10.1053/j.gastro.2020.04.014.
[14]
Choi MG , Jung HK . Health related quality of life in functional gastrointestinal disorders in Asia[J]. J Neurogastroenterol Motil, 2011，17(3):245-251. DOI:
10.5056/jnm.2011.17.3.245
.
[15]
张璐，段丽萍，刘懿萱，等. 中国人群肠易激综合征患病率和相关危险因素的Meta分析[J]. 中华内科杂志， 2014，53(12):969-975. DOI:
10.3760/cma.j.issn.0578-1426.2014.12.011
.
[16]
Long Y , Huang Z , Deng Y ,et al. Prevalence and risk factors for functional bowel disorders in South China: a population based study using the Rome Ⅲ criteria[J]. Neurogastroenterol Motil, 2017,29(1):10. DOI:
10.1111/nmo.12897
.
[17]
Sperber AD , Dumitrascu D , Fukudo S ,et al. The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation Working Team literature review[J]. Gut, 2017,66(6):1075-1082. DOI:
10.1136/gutjnl-2015-311240
.
[18]
Creed F . Review article: the incidence and risk factors for irritable bowel syndrome in population-based studies[J]. Aliment Pharmacol Ther， 2019，50(5):507-516. DOI:
10.1111/apt.15396
.
[19]
Liu JS , Hou XH . A review of the irritable bowel syndrome investigation on epidemiology, pathogenesis and pathophysiology in China[J]. J Gastroenterol Hepatol, 2011，26Suppl 3:88-93. DOI:
10.1111/j.1440-1746.2011.06641.x
.
[20]
Le Nevé B , Brazeilles R , Derrien M ,et al. Lactulose challenge determines visceral sensitivity and severity of symptoms in patients with irritable bowel syndrome[J]. Clin Gastroenterol Hepatol, 2016，14(2):226-233.e1-3. DOI:
10.1016/j.cgh.2015.09.039
.
[21]
王维达，方秀才，朱丽明，等. 肠易激综合征患者症状发作与饮食关系的调查[J]. 胃肠病学， 2012，17(2):110-114. DOI:
10.3969/j.issn.1008-7125.2012.02.012
.
[22]
[23]
[24]
Xing ZX , Hou XH , Zhou K ,et al. The impact of parental-rearing styles on irritable bowel syndrome in adolescents: a school-based study[J]. J Gastroenterol Hepatol, 2014，29(3):463-468. DOI:
10.1111/jgh.12388
.
[25]
Black CJ , Ford AC . Global burden of irritable bowel syndrome: trends, predictions and risk factors[J]. Nat Rev Gastroenterol Hepatol, 2020，17(8):473-486. DOI:
10.1038/s41575-020-0286-8
.
[26]
Halmos EP , Power VA , Shepherd SJ ,et al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome[J]. Gastroenterology, 2014,146(1):67-75.e5. DOI:
10.1053/j.gastro.2013.09.046
.
[27]
Klem F , Wadhwa A , Prokop LJ ,et al. Prevalence, risk factors, and outcomes of irritable bowel syndrome after infectious enteritis: a systematic review and meta-analysis[J]. Gastroenterology, 2017，152(5):1042-1054.e1. DOI:
10.1053/j.gastro.2016.12.039
.
[28]
Wang LH , Fang XC , Pan GZ . Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis[J]. Gut， 2004，53(8):1096-1101. DOI:
10.1136/gut.2003.021154
.
[29]
Halvorson HA , Schlett CD , Riddle MS . Postinfectious irritable bowel syndrome—a meta-analysis[J]. Am J Gastroenterol, 2006，101(8):1894-1899. DOI:
10.1111/j.1572-0241.2006.00654.x
.
[30]
Longstreth GF , Yao JF . Irritable bowel syndrome and surgery: a multivariable analysis[J]. Gastroenterology, 2004，126(7):1665-1673. DOI:
10.1053/j.gastro.2004.02.020
.
[31]
李莉，熊理守. 肠易激综合征的流行病学调查[J]. 中华消化杂志， 2015,35(7):446-450. DOI:
10.3760/cma.j.issn.0254-1432.2015.07.006
.
[32]
熊理守，彭穗，陈为，等. 肠易激综合征患者的就医行为及其影响因素[J]. 中华全科医师杂志， 2010，9(12):829-832. DOI:
10.3760/cma.j.issn.1671-7368.2010.12.006
.
[33]
Gralnek IM , Hays RD , Kilbourne A ,et al. The impact of irritable bowel syndrome on health-related quality of life[J]. Gastroenterology, 2000，119(3):654-660. DOI:
10.1053/gast.2000.16484
.
[34]
Bulut Çakmak B , Ōzkula G , Isikli S ,et al. Anxiety, depression, and anger in functional gastrointestinal disorders: a cross-sectional observational study[J]. Psychiatry Res, 2018，268:368-372. DOI:
10.1016/j.psychres.2018.06.046
.
[35]
Aziz I , Palsson OS , Törnblom H ,et al. The prevalence and impact of overlapping Rome Ⅳ-diagnosed functional gastrointestinal disorders on somatization, quality of life, and healthcare utilization: a cross-sectional general population study in three countries[J]. Am J Gastroenterol, 2018，113(1):86-96. DOI:
10.1038/ajg.2017.421
.
[36]
黄丹，梁列新，方秀才，等. 精神心理因素对腹泻型肠易激综合征患者生命质量的影响[J]. 中华消化杂志， 2015，35(9):599-605. DOI:
10.3760/cma.j.issn.0254-1432.2015.09.008
.
[37]
Drossman DA , Hasler WL . Rome Ⅳ-functional GI disorders: disorders of gut-brain interaction[J]．Gastroenterology, 2016，150(6):1257-1261. DOI:
10.1053/j.gastro.2016.03.035
.
[38]
Gwee KA , Gonlachanvit S , Ghoshal UC ,et al. Second Asian consensus on irritable bowel syndrome[J]．J Neurogastroenterol Motil, 2019，25(3):343-362. DOI:
10.5056/jnm19041
.
[39]
Koloski NA , Jones M , Kalantar J ,et al. The brain-gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study[J]. Gut, 2012，61(9):1284-1290. DOI:
10.1136/gutjnl-2011-300474
.
[40]
许东，王承党，李晓青，等. 腹泻型肠易激综合征合并心理异常对肠道症状的影响[J]. 中华消化杂志， 2018，38(9):603-608. DOI:
10.3760/cma.j.issn.0254-1432.2018.09.007
.
[41]
王曦，李蒙，胡玥，等. 蓝斑核促肾上腺皮质激素释放激素系统对肠易激综合征大鼠内脏敏感性的影响[J]. 中华消化杂志， 2020，40(1):40-44. DOI:
10.3760/cma.j.issn.0254-1432.2020.01.008
.
[42]
Zuo XL , Li YQ , Huang KM ,et al. Alterations in cerebral potentials evoked by rectal distention and drinking ice water in patients with irritable bowel syndrome[J]. J Gastroenterol Hepatol, 2006，21(12):1844-1849. DOI:
10.1111/j.1440-1746.2006.04176.x
.
[43]
李田，季公俊，辛海威，等. 腹泻型肠易激综合征患者直肠气囊扩张刺激的脑功能研究[J]．中华消化杂志， 2017，37(1):24-27. DOI:
10.3760/cma.j.issn.0254-1432.2017.01.008
.
[44]
Gwee KA , Lu CL , Ghoshal UC . Epidemiology of irritable bowel syndrome in Asia: something old, something new, something borrowed[J]. J Gastroenterol Hepatol, 2009，24(10):1601-1607. DOI:
10.1111/j.1440-1746.2009.05984.x
.
[45]
Farzaei MH , Bahramsoltani R , Abdollahi M ,et al. The role of visceral hypersensitivity in irritable bowel syndrome: pharmacological targets and novel treatments[J]. J Neurogastroenterol Motil, 2016，22(4):558-574. DOI:
10.5056/jnm16001
.
[46]
Ludidi S , Mujagic Z , Jonkers D ,et al. Markers for visceral hypersensitivity in patients with irritable bowel syndrome[J]. Neurogastroenterol Motil, 2014,26(8):1104-1111. DOI:
10.1111/nmo.12365
.
[47]
Posserud I , Syrous A , Lindström L ，et al. Altered rectal perception in irritable bowel syndrome is associated with symptom severity[J]. Gastroenterology, 2007，133(4):1113-1123. DOI:
10.1053/j.gastro.2007.07.024
.
[48]
Törnblom H , Van Oudenhove L , Tack J ,et al. Interaction between preprandial and postprandial rectal sensory and motor abnormalities in IBS[J]. Gut， 2014，63(9):1441-1449. DOI:
10.1136/gutjnl-2013-305853
.
[49]
Ludidi S , Conchillo JM , Keszthelyi D ,et al. Rectal hypersensitivity as hallmark for irritable bowel syndrome: defining the optimal cutoff[J]．Neurogastroenterol Motil, 2012，24(8):729-733, e345-e346. DOI:
10.1111/j.1365-2982.2012.01926.x
.
[50]
Liu L , Liu BN , Chen S ,et al. Visceral and somatic hypersensitivity, autonomic cardiovascular dysfunction and low-grade inflammation in a subset of irritable bowel syndrome patients[J]. J Zhejiang Univ Sci B, 2014，15(10):907-914. DOI:
10.1631/jzus.B1400143
.
[51]
Matricon J , Meleine M , Gelot A ,et al. Review article: associations between immune activation, intestinal permeability and the irritable bowel syndrome[J]. Aliment Pharmacol Ther, 2012，36(11-12):1009-1031. DOI:
10.1111/apt.12080
.
[52]
DuPont AW , Jiang ZD , Harold SA ,et al. Motility abnormalities in irritable bowel syndrome[J]. Digestion, 2014,89(2):119-123. DOI:
10.1159/000356314
.
[53]
Fassov J , Lundby L , Worsøe J ,et al. A randomised, controlled study of small intestinal motility in patients treated with sacral nerve stimulation for irritable bowel syndrome[J]. BMC Gastroenterol, 2014，14:111. DOI:
10.1186/1471-230X-14-111
.
[54]
Park JH , Baek YH , Park DI ,et al. Analysis of rectal dynamic and static compliances in patients with irritable bowel syndrome[J]. Int J Colorectal Dis, 2008，23(7):659-664. DOI:
10.1007/s00384-008-0469-1
.
[55]
Törnblom H , Van Oudenhove L , Sadik R ,et al. Colonic transit time and IBS symptoms: what’s the link？[J]. Am J Gastroenterol， 2012，107(5):754-760. DOI:
10.1038/ajg.2012.5
.
[56]
Kanazawa M , Palsson OS , van Tilburg MA ,et al. Motility response to colonic distention is increased in postinfectious irritable bowel syndrome (PI-IBS)[J]. Neurogastroenterol Motil, 2014，26(5):696-704. DOI:
10.1111/nmo.12318
.
[57]
Lee OY . Asian motility studies in irritable bowel syndrome[J]. J Neurogastroenterol Motil, 2010，16(2):120-130. DOI:
10.5056/jnm.2010.16.2.120
.
[58]
Sinagra E , Pompei G , Tomasello G ,et al. Inflammation in irritable bowel syndrome: myth or new treatment target？[J]. World J Gastroenterol, 2016，22(7):2242-2255. DOI:
10.3748/wjg.v22.i7.2242
.
[59]
Bashashati M , Moossavi S , Cremon C ,et al. Colonic immune cells in irritable bowel syndrome: a systematic review and meta-analysis[J/OL]. Neurogastroenterol Motil, 2018，30(1) (2017-08-29)[2020-11-16]. https://doi.org/10.1111/nmo.13192.
[60]
Liu YX , Zhang L , Wang XQ ,et al. Similar fecal microbiota signatures in patients with diarrhea-predominant irritable bowel syndrome and patients with depression[J]. Clin Gastroenterol Hepatol, 2016,14(11):1602-1611.e5. DOI:
10.1016/j.cgh.2016.05.033
.
[61]
Hughes PA , Harrington AM , Castro J ,et al. Sensory neuro-immune interactions differ between irritable bowel syndrome subtypes[J]. Gut, 2013，62(10):1456-1465. DOI:
10.1136/gutjnl-2011-301856
.
[62]
Martin-Viñas JJ , Quigley EM . Immune response in irritable bowel syndrome: a systematic review of systemic and mucosal inflammatory mediators[J]. J Dig Dis, 2016，17(9):572-581. DOI:
10.1111/1751-2980.12379
.
[63]
李延青，张海燕，左秀丽，等. 肠易激综合征患者肠黏膜Th1/Th2漂移的研究[J]. 中华消化杂志， 2004，24(12):728-731. DOI:
10.3760/j.issn:0254-1432.2004.12.007
.
[64]
Xu XJ , Zhang YL , Liu L ,et al. Increased expression of nerve growth factor correlates with visceral hypersensitivity and impaired gut barrier function in diarrhoea-predominant irritable bowel syndrome: a preliminary explorative study[J]. Aliment Pharmacol Ther, 2017,45(1):100-114. DOI:
10.1111/apt.13848
.
[65]
李珊，杨希林，费贵军，等. 肠易激综合征模型大鼠结肠肌间神经丛钙视网膜蛋白阳性神经元增加[J]. 胃肠病学和肝病学杂志， 2019，28(4):395-399. DOI:
10.3969/j.issn.1006-5709.2019.04.009
.
[66]
Zhang L , Wang RY , Bai T ，et al. EphrinB2/ephB2-mediated myenteric synaptic plasticity: mechanisms underlying the persistent muscle hypercontractility and pain in postinfectious IBS[J]. FASEB J, 2019，33(12):13644-13659. DOI:
10.1096/fj.201901192R
.
[67]
Koloski NA , Jones M , Talley NJ . Evidence that independent gut-to-brain and brain-to-gut pathways operate in the irritable bowel syndrome and functional dyspepsia: a 1-year population-based prospective study[J]. Aliment Pharmacol Ther, 2016，44(6):592-600. DOI:
10.1111/apt.13738
.
[68]
Pinto-Sanchez MI , Ford AC , Avila CA ,et al. Anxiety and depression increase in a stepwise manner in parallel with multiple FGIDs and symptom severity and frequency[J]. Am J Gastroenterol, 2015，110(7):1038-1048. DOI:
10.1038/ajg.2015.128
.
[69]
Tillisch K , Mayer EA , Labus JS . Quantitative meta-analysis identifies brain regions activated during rectal distension in irritable bowel syndrome[J]. Gastroenterology, 2011，140(1):91-100. DOI:
10.1053/j.gastro.2010.07.053
.
[70]
de Punder K , Pruimboom L . Stress induces endotoxemia and low-grade inflammation by increasing barrier permeability[J]. Front Immunol, 2015，6:223. DOI:
10.3389/fimmu.2015.00223
.
[71]
Vanuytsel T , Van Wanrooy S , Vanheel H ,et al. Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism[J]. Gut， 2014，63(8):1293-1299. DOI:
10.1136/gutjnl-2013-305690
.
[72]
Bednarska O , Walter SA , Casado-Bedmar M ,et al. Vasoactive intestinal polypeptide and mast cells regulate increased passage of colonic bacteria in patients with irritable bowel syndrome[J]. Gastroenterology， 2017，153(4):948-960.e3. DOI:
10.1053/j.gastro.2017.06.051
.
[73]
Zhang JD , Song LJ , Wang YJ ,et al. Beneficial effect of butyrate-producing
Lachnospiraceae on stress-induced visceral hypersensitivity in rats
[J]. J Gastroenterol Hepatol, 2019,34(8):1368-1376. DOI:
10.1111/jgh.14536
.
[74]
Hong GC , Li Y , Yang M ,et al. Gut fungal dysbiosis and altered bacterial-fungal interaction in patients with diarrhea-predominant irritable bowel syndrome: an explorative study[J/OL]. Neurogastroenterol Motil， 2020，32(11):e13891(2020-05-25)[2020-11-16]. https://doi.org/10.1111/nmo.13891.
[75]
Zhuang XJ , Xiong LS , Li L ,et al. Alterations of gut microbiota in patients with irritable bowel syndrome: a systematic review and meta-analysis[J]. J Gastroenterol Hepatol, 2017，32(1):28-38. DOI:
10.1111/jgh.13471
.
[76]
Duan RQ , Zhu SW , Wang B ,et al. Alterations of gut microbiota in patients with irritable bowel syndrome based on 16S rRNA-targeted sequencing: a systematic review[J]. Clin Transl Gastroenterol, 2019，10(2):e00012(2019-02-27)[2020-11-16]. https://doi.org/10.14309/ctg.0000000000000012.
[77]
Jalanka-Tuovinen J , Salojärvi J , Salonen A ,et al. Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome[J]. Gut, 2014,63(11):1737-1745. DOI:
10.1136/gutjnl-2013-305994
.
[78]
Sun QH , Jia Q , Song LJ ,et al. Alterations in fecal short-chain fatty acids in patients with irritable bowel syndrome: a systematic review and meta-analysis[J/OL]. Medicine, 2019，98(7):e14513(2019-02-15)[2020-11-16]. https://doi.org/10.1097/MD.0000000000014513.
[79]
Shah A , Talley NJ , Jones M ,et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis of case-control studies[J]. Am J Gastroenterol, 2020，115(2):190-201. DOI:
10.14309/ajg.0000000000000504
.
[80]
Ghoshal UC , Nehra A , Mathur A ,et al. A meta-analysis on small intestinal bacterial overgrowth in patients with different sub-types of irritable bowel syndrome[J]. J Gastroenterol Hepatol, 2020,35(6):922-931. DOI:
10.1111/jgh.14938
.
[81]
Drossman DA . 罗马Ⅲ：功能性胃肠病[M]. 柯美云，方秀才，译. 3版．北京：科学出版社， 2008：432-497.
[82]
Palsson OS , Whitehead W , Törnblom H ,et al. Prevalence of Rome Ⅳ functional bowel disorders among adults in the United States, Canada, and the United Kingdom[J]. Gastroenterology, 2020，158(5):1262-1273. DOI:
10.1053/j.gastro.2019.12.021
.
[83]
Black CJ , Yiannakou Y , Houghton LA ,et al. Epidemiological, clinical, and psychological characteristics of individuals with self-reported irritable bowel syndrome based on the Rome Ⅳ vs Rome Ⅲ criteria[J]. Clin Gastroenterol Hepatol, 2020，18(2):392-398. DOI:
10.1016/j.cgh.2019.05.037
.
[84]
Aziz I , Törnblom H , Palsson OS ,et al. How the change in IBS criteria from Rome Ⅲ to Rome Ⅳ impacts on clinical characteristics and key pathophysiological factors[J]. Am J Gastroenterol, 2018,113(7):1017-1025. DOI:
10.1038/s41395-018-0074-z
.
[85]
Wang B , Zhao W , Zhao CS ,et al. What impact do Rome Ⅳ criteria have on patients with IBS in China？[J]. Scand J Gastroenterol, 2019,54(12):1433-1440. DOI:
10.1080/00365521.2019.1698650
.
[86]
Ghoshal UC , Gwee KA , Chen MH ,et al. Development, translation and validation of enhanced Asian Rome Ⅲ questionnaires for diagnosis of functional bowel diseases in major Asian languages: a Rome Foundation-Asian Neurogastroenterology and Motility Association Working Team report[J]. J Neurogastroenterol Motil, 2015，21(1):83-92. DOI:
10.5056/jnm14045
.
[87]
潘国宗，鲁素彩，韩少梅. 肠易激综合征症状学诊断标准的研究[J]. 中华内科杂志， 1999，38(2):81-84. DOI:
10.3760/j.issn:0578-1426.1999.02.003
.
[88]
陈惠新，许岸高，熊理守，等. 肠易激综合征症状学诊断标准的特异性研究[J]．胃肠病学和肝病学杂志， 2004，13(4):400-402. DOI:
10.3969/j.issn.1006-5709.2004.04.023
.
[89]
Bai T , Wang WF , Zhang L ,et al. Positive endoscopic and ultrasonographic findings in patients with symptom-diagnosed functional gastrointestinal disorder: data from a Chinese cross-sectional study[J]. J Dig Dis, 2018，19(12):759-765. DOI:
10.1111/1751-2980.12693
.
[90]
Lu CL , Chen CY , Lang HC ，et al. Current patterns of irritable bowel syndrome in Taiwan: the Rome Ⅱ questionnaire on a Chinese population[J]. Aliment Pharmacol Ther, 2003，18(11-12):1159-1169. DOI:
10.1046/j.1365-2036.2003.01711.x
.
[91]
Canavan C , Card T , West J . The incidence of other gastroenterological disease following diagnosis of irritable bowel syndrome in the UK: a cohort study[J/OL]. PLoS One, 2014，9(9):e106478(2014-09-19)[2020-11-16]. https://doi.org/10.1371/journal.pone.0106478.
[92]
王伟岸，钱家鸣，潘国宗. 肠易激综合症的诊断标准和鉴别诊断[J]. 胃肠病学和肝病学杂志， 2001，10(2):106-109. DOI:
10.3969/j.issn.1006-5709.2001.02.004
.
[93]
Chey WD , Nojkov B , Rubenstein JH ,et al. The yield of colonoscopy in patients with non-constipated irritable bowel syndrome: results from a prospective, controlled US trial[J]. Am J Gastroenterol, 2010,105(4):859-865. DOI:
10.1038/ajg.2010.55
.
[94]
Patel P , Bercik P , Morgan DG ,et al. Prevalence of organic disease at colonoscopy in patients with symptoms compatible with irritable bowel syndrome: cross-sectional survey[J]．Scand J Gastroenterol, 2015，50(7):816-823. DOI:
10.3109/00365521.2015.1007079
.
[95]
戈之铮，李晓波，刘文忠，等. 报警症状在胃肠道疾病诊断中的作用[J]. 胃肠病学， 2005，10(4):198-202. DOI:
10.3969/j.issn.1008-7125.2005.04.002
.
[96]
万德森. 中国结直肠癌住院病例临床病理特点及变化趋势——18家医院31 246例初步分析[C]∥中国科协，中国抗癌协会，中华预防医学会，等.第十三届中国科协年会第18分会场——癌症流行趋势和防控策略研究研讨会论文集，天津，2011. 北京：中国科学技术协会学术部， 2011：174-181.
[97]
中华医学会消化病学分会. 中国结直肠肿瘤筛查、早诊早治和综合预防共识意见(一)[J]. 中华消化杂志， 2012,32(1):1-10. DOI:
10.3760/cma.j.issn.0254-1432.2012.01.001
.
[98]
Yao X , Yang YS , Cui LH ,et al. Subtypes of irritable bowel syndrome on Rome Ⅲ criteria: a multicenter study[J]. J Gastroenterol Hepatol, 2012，27(4):760-765. DOI:
10.1111/j.1440-1746.2011.06930.x
.
[99]
Moayyedi P , Mearin F , Azpiroz F ,et al. Irritable bowel syndrome diagnosis and management: a simplified algorithm for clinical practice[J]. United European Gastroenterol J, 2017，5(6):773-788. DOI:
10.1177/2050640617731968
.
[100]
Rey E , Balboa A , Mearin F . Chronic constipation, irritable bowel syndrome with constipation and constipation with pain/discomfort: similarities and differences[J]. Am J Gastroenterol, 2014,109(6):876-884. DOI:
10.1038/ajg.2014.18
.
[101]
Suttor VP , Prott GM , Hansen RD ,et al. Evidence for pelvic floor dyssynergia in patients with irritable bowel syndrome[J]. Dis Colon Rectum, 2010，53(2):156-160. DOI:
10.1007/DCR.0b013e3181c188e8
.
[102]
Wong RK , Palsson OS , Turner MJ ,et al. Inability of the Rome Ⅲ criteria to distinguish functional constipation from constipation-subtype irritable bowel syndrome[J]. Am J Gastroenterol, 2010，105(10):2228-2234. DOI:
10.1038/ajg.2010.200
.
[103]
辛海威，方秀才，柯美云. 功能性便秘和便秘型肠易激综合征：我们能鉴别吗？[J]．胃肠病学和肝病学杂志， 2013,22(2):158-162. DOI:
10.3969/j.issn.1006-5709.2013.02.020
.
[104]
Rasmussen S , Jensen TH , Henriksen SL ，et al. Overlap of symptoms of gastroesophageal reflux disease, dyspepsia and irritable bowel syndrome in the general population[J]．Scand J Gastroenterol, 2015,50(2):162-169. DOI:
10.3109/00365521.2014.983157
.
[105]
Wang AJ , Liao XH , Xiong LS ,et al. The clinical overlap between functional dyspepsia and irritable bowel syndrome based on Rome Ⅲ criteria[J]. BMC Gastroenterol, 2008，8:43. DOI:
10.1186/1471-230X-8-43
.
[106]
von Wulffen M , Talley NJ , Hammer J ,et al. Overlap of irritable bowel syndrome and functional dyspepsia in the clinical setting: prevalence and risk factors[J]. Dig Dis Sci, 2019，64(2):480-486. DOI:
10.1007/s10620-018-5343-6
.
[107]
de Bortoli N , Martinucci I , Bellini M ,et al. Overlap of functional heartburn and gastroesophageal reflux disease with irritable bowel syndrome[J]．World J Gastroenterol, 2013，19(35):5787-5797. DOI:
10.3748/wjg.v19.i35.5787
.
[108]
孙艳芳，李延青，王亚平. 功能性消化不良重叠肠易激综合征患者的消化道症状和生活质量特点[J]. 胃肠病学， 2006，11(8):492-494. DOI:
10.3969/j.issn.1008-7125.2006.08.012
.
[109]
[110]
常敏，陈卫，方秀才，等. 腹泻型肠易激综合征患者肠外症状分析[J]. 胃肠病学， 2010，15(11):654-656. DOI:
10.3969/j.issn.1008-7125.2010.11.004
.
[111]
Zhu LM , Huang D , Shi LL ,et al. Intestinal symptoms and psychological factors jointly affect quality of life of patients with irritable bowel syndrome with diarrhea[J]. Health Qual Life Outcomes, 2015，13:49. DOI:
10.1186/s12955-015-0243-3
.
[112]
Tang YR , Yang WW , Wang YL ,et al. Sex differences in the symptoms and psychological factors that influence quality of life in patients with irritable bowel syndrome[J]. Eur J Gastroenterol Hepatol, 2012，24(6):702-707. DOI:
10.1097/MEG.0b013e328351b2c2
.
[113]
Drossman DA , Chang L , Bellamy N ,et al. Severity in irritable bowel syndrome: a Rome Foundation Working Team report[J]. Am J Gastroenterol, 2011，106(10):1749-1759. DOI:
10.1038/ajg.2011.201
.
[114]
Drossman DA . 功能性胃肠病多维度临床资料剖析(中文翻译版)[M]. 蓝宇，方秀才，译. 2版. 北京：科学出版社， 2017：72-104.
[115]
Ford AC , Lacy BE , Harris LA ,et al. Effect of antidepressants and psychological therapies in irritable bowel syndrome: an updated systematic review and meta-analysis[J]. Am J Gastroenterol, 2019，114(1):21-39. DOI:
10.1038/s41395-018-0222-5
.
[116]
Chey WD , Kurlander J , Eswaran S . Irritable bowel syndrome: a clinical review[J]. JAMA, 2015，313(9):949-958. DOI:
10.1001/jama.2015.0954
.
[117]
Dhaliwal SK , Hunt RH . Doctor-patient interaction for irritable bowel syndrome in primary care: a systematic perspective[J]. Eur J Gastroenterol Hepatol, 2004,16(11):1161-1166. DOI:
10.1097/00042737-200411000-00013
.
[118]
Patcharatrakul T , Juntrapirat A , Lakananurak N ,et al. Effect of structural individual low-FODMAP dietary advice vs. brief advice on a commonly recommended diet on IBS symptoms and intestinal gas production[J]. Nutrients, 2019，11(12):2856. DOI:
10.3390/nu11122856
.
[119]
Dionne J , Ford AC , Yuan YH ,et al. A systematic review and meta-analysis evaluating the efficacy of a gluten-free diet and a low FODMAPs diet in treating symptoms of irritable bowel syndrome[J]. Am J Gastroenterol, 2018，113(9):1290-1300. DOI:
10.1038/s41395-018-0195-4
.
[120]
Eswaran SL , Chey WD , Han-Markey T ,et al. A randomized controlled trial comparing the low FODMAP diet vs. modified NICE guidelines in US adults with IBS-D[J]. Am J Gastroenterol, 2016，111(12):1824-1832. DOI:
10.1038/ajg.2016.434
.
[121]
Atkinson W , Sheldon TA , Shaath N ,et al. Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial[J]. Gut, 2004，53(10):1459-1464. DOI:
10.1136/gut.2003.037697
.
[122]
Johannesson E , Simrén M , Strid H ,et al. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial[J]. Am J Gastroenterol, 2011,106(5):915-922. DOI:
10.1038/ajg.2010.480
.
[123]
Johannesson E , Ringström G , Abrahamsson H ,et al. Intervention to increase physical activity in irritable bowel syndrome shows long-term positive effects[J]. World J Gastroenterol, 2015,21(2):600-608. DOI:
10.3748/wjg.v21.i2.600
.
[124]
Shahabi L , Naliboff BD , Shapiro D . Self-regulation evaluation of therapeutic yoga and walking for patients with irritable bowel syndrome: a pilot study[J]. Psychol Health Med, 2016，21(2):176-188. DOI:
10.1080/13548506.2015.1051557
.
[125]
Schneider A , Rosenberger S , Bobardt J ,et al. Self-help guidebook improved quality of life for patients with irritable bowel syndrome[J/OL]. PLoS One, 2017，12(7):e0181764(2017-07-25)[2020-11-16]. https://doi.org/10.1371/journal.pone.0181764.
[126]
Liegl G , Plessen CY , Leitner A ,et al. Guided self-help interventions for irritable bowel syndrome: a systematic review and meta-analysis[J]. Eur J Gastroenterol Hepatol, 2015，27(10):1209-1221. DOI:
10.1097/MEG.0000000000000428
.
[127]
Lackner JM , Jaccard J , Keefer L ，et al. Improvement in gastrointestinal symptoms after cognitive behavior therapy for refractory irritable bowel syndrome[J]. Gastroenterology, 2018,155(1):47-57. DOI:
10.1053/j.gastro.2018.03.063
.
[128]
Everitt HA , Landau S , O′Reilly G ,et al. Cognitive behavioural therapy for irritable bowel syndrome: 24-month follow-up of participants in the ACTIB randomised trial[J]. Lancet Gastroenterol Hepatol, 2019，4(11):863-872. DOI:
10.1016/S2468-1253(19)30243-2
.
[129]
Martínez-Vázquez MA , Vázquez-Elizondo G , González-González JA ,et al. Effect of antispasmodic agents, alone or in combination, in the treatment of irritable bowel syndrome: systematic review and meta-analysis[J]. Rev Gastroenterol Mex, 2012，77(2):82-90. DOI:
10.1016/j.rgmx.2012.04.002
.
[130]
Zheng L , Lai YL , Lu WM ,et al. Pinaverium reduces symptoms of irritable bowel syndrome in a multicenter, randomized, controlled trial[J]. Clin Gastroenterol Hepatol， 2015，13(7):1285-1292. DOI:
10.1016/j.cgh.2015.01.015
.
[131]
Clavé P , Acalovschi M , Triantafillidis JK ,et al. Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome[J]. Aliment Pharmacol Ther, 2011,34(4):432-442. DOI:
10.1111/j.1365-2036.2011.04730.x
.
[132]
Wittmann T , Paradowski L , Ducrotte P ,et al. Clinical trial: the efficacy of alverine citrate/simeticone combination on abdominal pain/discomfort in irritable bowel syndrome—a randomized, double-blind, placebo-controlled study[J]. Aliment Pharmacol Ther, 2009，31(6):615-624. DOI:
10.1111/j.1365-2036.2009.04216.x
.
[133]
Liang D , Zhong LD , Ji G . Irritable bowel syndrome and functional constipation management with integrative medicine: a systematic review[J]. World J Clin Cases， 2019，7(21):3486-3504. DOI:
10.12998/wjcc.v7.i21.3486
.
[134]
Cann PA , Read NW , Holdworth CD ,et al. Role of loperamide and placebo in management of irritable bowel syndrome (IBS)[J]. Dig Dis Sci， 1984，29(3):239-247. DOI:
10.1007/BF01296258
.
[135]
Efskind PS , Bernklev T , Vatn MH ,et al. A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome[J]. Scand J Gastroenterol, 1996，31(5):463-468. DOI:
10.3109/00365529609006766
.
[136]
Chang FY , Lu CL , Chen CY ,et al. Efficacy of dioctahedral smectite in treating patients of diarrhea-predominant irritable bowel syndrome[J]. J Gastroenterol Hepatol, 2007，22(12):2266-2272. DOI:
10.1111/j.1440-1746.2007.04895.x
.
[137]
Ducrotte P , Dapoigny M , Bonaz B ,et al. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial[J]. Aliment Pharmacol Ther, 2005，21(4):435-444. DOI:
10.1111/j.1365-2036.2005.02330.x
.
[138]
Jin Y , Ren XY , Li GP ,et al. Beneficial effects of rifaximin in post-infectious irritable bowel syndrome mouse beyond gut microbiota[J]. J Gastroenterol Hepatol, 2018，33(2):443-452. DOI:
10.1111/jgh.13841
.
[139]
Collins SM , Bercik P . The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease[J]. Gastroenterology, 2009，136(6):2003-2014. DOI:
10.1053/j.gastro.2009.01.075
.
[140]
Ford AC , Harris LA , Lacy BE ,et al. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome[J]. Aliment Pharmacol Ther, 2018，48(10):1044-1060. DOI:
10.1111/apt.15001
.
[141]
Pimentel M , Lembo A , Chey WD ,et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation[J]. N Engl J Med, 2011，364(1):22-32. DOI:
10.1056/NEJMoa1004409
.
[142]
Schoenfeld P , Pimentel M , Chang L ,et al. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials[J]. Aliment Pharmacol Ther, 2014,39(10):1161-1168. DOI:
10.1111/apt.12735
.
[143]
Sharara AI , Aoun E , Abdul-Baki H ,et al. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence[J]. Am J Gastroenterol, 2006，101(2):326-333. DOI:
10.1111/j.1572-0241.2006.00458.x
.
[144]
Lembo A , Rao SSC , Heimanson Z ,et al. Abdominal pain response to rifaximin in patients with irritable bowel syndrome with diarrhea[J/OL]. Clin Transl Gastroenterol, 2020，11(3):e00144(2020-03-06)[2020-11-16]．https://doi.org/10.14309/ctg.0000000000000144.
[145]
Ghoshal UC , Srivastava D , Misra A ,et al. A proof of concept study showing antibiotics to be more effective in irritable bowel syndrome with than without small intestinal bacterial overgrowth: a randomized, double blind, placebo controlled trial[J]. Eur J Gastroenterol Hepatol， 2016，28(3):281-289. DOI:
10.1097/MEG.0000000000000557
.
[146]
Pimentel M , Chow EJ , Lin HC . Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study[J]. Am J Gastroenterol, 2003，98(2):412-419. DOI:
10.1111/j.1572-0241.2003.07234.x
.
[147]
Yang J , Lee HR , Low K ,et al. Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS[J]. Dig Dis Sci, 2008，53(1):169-174. DOI:
10.1007/s10620-007-9839-8
.
[148]
Rezaie A , Heimanson Z , McCallum R ,et al. Lactulose breath testing as a predictor of response to rifaximin in patients with irritable bowel syndrome with diarrhea[J]. Am J Gastroenterol, 2019，114(12):1886-1893. DOI:
10.14309/ajg.0000000000000444
.
[149]
Barkin JA , Keihanian T , Barkin JS ,et al. Preferential usage of rifaximin for the treatment of hydrogen-positive small intestinal bacterial overgrowth[J]. Rev Gastroenterol Peru, 2019，39(2):111-115.
[150]
Li Y , Hong GC , Yang M ,et al. Fecal bacteria can predict the efficacy of rifaximin in patients with diarrhea-predominant irritable bowel syndrome[J]. Pharmacol Res, 2020，159:104936. DOI:
10.1016/j.phrs.2020.104936
.
[151]
Zhao J , Zheng X , Chu H ,et al. A study of the methodological and clinical validity of the combined lactulose hydrogen breath test with scintigraphic oro-cecal transit test for diagnosing small intestinal bacterial overgrowth in IBS patients[J]. Neurogastroenterol Motil, 2014，26(6):794-802. DOI:
10.1111/nmo.12331
.
[152]
Zhuang XJ , Tian ZY , Luo M ,et al. Short-course rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome[J]. BMC Gastroenterology, 2020，20(1):187. DOI:
10.1186/s12876-020-01336-6
.
[153]
Lembo A , Pimentel M , Rao SS ,et al. Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome[J]. Gastroenterology, 2016，151(6):1113-1121. DOI:
10.1053/j.gastro.2016.08.003
.
[154]
Cash BD , Pimentel M , Rao SSC ,et al. Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial[J]．Ther Adv Gastroenterol， 2017,10(9):689-699. DOI:
10.1177/1756283X17726087
.
[155]
Awad RA , Camacho S . A randomized, double-blind, placebo-controlled trial of polyethylene glycol effects on fasting and postprandial rectal sensitivity and symptoms in hypersensitive constipation predominant irritable bowel syndrome[J]. Colorectal Dis, 2010,12(11):1131-1138. DOI:
10.1111/j.1463-1318.2009.01990.x
.
[156]
Chapman RW , Stanghellini V , Geraint M ,et al. Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome[J]. Am J Gastroenterol, 2013，108(9):1508-1515. DOI:
10.1038/ajg.2013.197
.
[157]
Enck P , Aziz Q , Barbara G ,et al. Irritable bowel syndrome[J/OL]. Nat Rev Dis Primers, 2016，2:16014(2016-03-24)[2020-11-16]．https://doi.org/10.1038/nrdp.2016.14.
[158]
聚卡波非钙协作组. 聚卡波非钙治疗便秘型肠易激综合征的随机、双盲、安慰剂对照多中心临床试验[J]．中华消化杂志， 2007，27(10):685-688. DOI:
10.3760/j.issn:0254-1432.2007.10.010
.
[159]
Black CJ , Burr NE , Quigley EMM ,et al. Efficacy of secretagogues in patients with irritable bowel syndrome with constipation: systematic review and network meta-analysis[J]. Gastroenterology, 2018,155(6):1753-1763. DOI:
10.1053/j.gastro.2018.08.021
.
[160]
Johnston JM , Kurtz CB , Macdougall JE ，et al. Linaclotide improves abdominal pain and bowel habits in a phase Ⅱb study of patients with irritable bowel syndrome and constipation[J]. Gastroenterology, 2010，139(6):1877-1886. DOI:
10.1053/j.gastro.2010.08.041
.
[161]
Chey WD , Lembo AJ , Lavins BJ ,et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety[J]. Am J Gastroenterol, 2012,107(11):1702-1712. DOI:
10.1038/ajg.2012.254
.
[162]
Rao S , Lembo AJ , Shiff SJ ,et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation[J]. Am J Gastroenterol, 2012，107(11):1714-1724. DOI:
10.1038/ajg.2012.255
.
[163]
Yang YS , Fang JY , Guo XZ ,et al. Linaclotide in irritable bowel syndrome with constipation: a phase 3 randomized trial in China and other regions[J]. J Gastroenterol Hepatol, 2018,33(5):980-989. DOI:
10.1111/jgh.14086
.
[164]
Li F , Fu T , Tong WD ，et al. Lubiprostone is effective in the treatment of chronic idiopathic constipation and irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials[J]. Mayo Clin Proc, 2016，91(4):456-468. DOI:
10.1016/j.mayocp.2016.01.015
.
[165]
Rahimi R , Abdollahi M . Herbal medicines for the management of irritable bowel syndrome: a comprehensive review[J]. World J Gastroenterol, 2012，18(7):589-600. DOI:
10.3748/wjg.v18.i7.589
.
[166]
Chen M , Tang TC , Wang Y ,et al. Randomized clinical trial: Tong-Xie-Yao-Fang granules versus placebo for patients with diarrhoea-predominant irritable bowel syndrome[J]. Aliment Pharmacol Ther, 2018，48(2):160-168. DOI:
10.1111/apt.14817
.
[167]
Zhang L , Luo B , Bai T ,et al. Effects of Tongxiening granule on colonic smooth muscle activity in an
ex vivo model: analysis of the mechanism of action
[J]. J Dig Dis, 2016,17Suppl 1:13-112. DOI:
10.1111/1751-2980.12389
.
[168]
Barbara G , Fukudo S , Drummond L ,et al. Tu1644-green kiwifruit compared to psyllium for the relief of constipation and improving digestive comfort in patients with functional constipation and constipation predominant irritable bowel syndrome—analysis of three international trial centers[J]. Gastroenterology, 2018，154(6Suppl 1):S979-980.
[169]
Dai YK , Li DY , Zhang YZ ,et al. Efficacy and safety of modified Tongxie Yaofang in diarrhea-predominant irritable bowel syndrome management: a meta-analysis of randomized, positive medicine controlled trials[J/OL]. PLoS One, 2018，13(2):e0192319(2018-02-06)[2020-11-16]. https://doi.org/10.1371/journal.pone.0192319.
备注信息
A
侯晓华，华中科技大学同济医学院附属协和医院消化内科，武汉 430022，Email:
nc.defudabe.tsuhhxuoh，电话：027-85726057
B
中文：中华医学会消化病学分会胃肠功能性疾病协作组，中华医学会消化病学分会胃肠动力学组. 2020年中国肠易激综合征专家共识意见[J].中华消化杂志，2020，40(12)：803-818. DOI：10.3760/cma.j.cn311367-20201116-00660.英文：Study Group of Functional Gastrointestinal Disorders, Study Group of Gastrointestinal Motility, Chinese Society of Gastroenterology, Chinese Medical Association. Chinese expert consensus of irritable bowel syndrome in 2020[J]. Chin J Dig, 2020，40(12)：803-818. DOI：10.3760/cma.j.cn311367-20201116-00660.
C
专家组所有成员均声明不存在利益冲突
评论 （0条）
注册 登录
时间排序
- 时间排序
暂无评论，发表第一条评论抢沙发
最新推荐
更多
中国毛霉病临床诊疗专家共识（2022）
中国医药教育协会真菌病专业委员会 等 中华内科杂志 2023,62(06)
中国隐匿性肝性脑病临床诊治专家共识意见
中华医学会消化病学分会肝胆疾病学组 中华消化杂志 2023,43(11)
中国慢性便秘专家共识意见(2019，广州)
中华医学会消化病学分会胃肠动力学组 等 中华消化杂志 2019,39(09)
中国肠易激综合征专家共识意见(2015年，上海)
中华医学会消化病学分会胃肠功能性疾病协作组 等 中华消化杂志 2016,36(05)
分享
详细信息
表
访问与引文
阅读权限
参考文献
访问与引用
访问数据
0
0
全部时间 最近30天 最近6个月 最近12个月
MedAI助手（体验版）
文档即答
智问智答
机器翻译
回答内容由人工智能生成，我社无法保证其准确性和完整性，该生成内容不代表我们的态度或观点，仅供参考。
生成快照
文献快照
文献快照
N/A
N/A
AI总结中
N/A
N/A
快照内容由人工智能生成，供您参考。
你好，我可以帮助您更好的了解本文，请向我提问您关注的问题。
0/50
很抱歉，当前对话已达到其限制。
使用"新建对话"按钮开启更多对话。
停止回答
0/2000
信息反馈
中文(简体)
英文
翻译
机器翻译功能由科大讯飞提供技术支持
回答内容由人工智能生成，我社无法保证其准确性和完整性，该生成内容不代表我们的态度或观点，仅供参考。
你好！ 今天我能为您提供什么帮助？
0/30
of
很抱歉，当前对话已达到其限制。
使用"新建对话"按钮开启更多对话。
停止回答
扩写 缩写 改写 翻译
0/2000
信息反馈
历史对话
本文全部
还没有聊天记录
设置
模式
纯净模式沉浸模式
字号
小中大
翻译
润色
扩写
缩写
复制
引用
